ARTICLE | Company News
TaiMed's ibalizumab gets breakthrough designation
February 28, 2015 2:37 AM UTC
WuXi PharmaTech Inc. (NYSE:WX) said FDA granted breakthrough designation to ibalizumab ( TMB-355) from its partner Taimed Biologics Inc. (GreTai:4147) to treat HIV.
TaiMed has completed a Phase IIb trial of IV ibalizumab and a Phase I trial of a subcutaneous formulation. The companies did not respond to inquiries about future development plans. ...